- Home
- CMBM vs TVRD Comparison
CMBM vs TVRD Comparison
Compare CMBM & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMBM | TVRD |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.6M | 36.8M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | CMBM | TVRD |
|---|---|---|
| Price | $1.41 | $3.89 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 131.6K | 37.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $220,195,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $18.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.23 | $3.50 |
| 52 Week High | $6.80 | $43.65 |
Technical Indicators
Market Signals| Indicator | CMBM | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 56.54 | 49.44 |
| Support Level | $1.10 | $3.81 |
| Resistance Level | $1.81 | $4.45 |
| Average True Range (ATR) | 0.11 | 0.21 |
| MACD | 0.03 | 0.01 |
| Stochastic Oscillator | 88.00 | 47.89 |
Price Performance
Historical ComparisonAbout CMBM Cambium Networks Corporation
Cambium Networks Corp provides wireless broadband networking infrastructure solutions for network operators, including medium-sized wireless Internet service providers, enterprises, and government agencies. The company geographically operates in North America; Europe, Middle East and Africa; Caribbean and Latin America; and Asia Pacific. It derives maximum revenue from North America.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.